VMVasilii Evgenevich Mamonov

Vasilii Evgenevich Mamonov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Vasilii Evgenevich Mamonov has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Total hip arthroplasty in patients with Gaucher disease: characteristics and outcomes

    by Vasily E. Mamonov, Yulya A. Chabaeva, Vladimir A. Khomenko, Rodion V. Ponomarev, Elena A. Lukina

    BACKGROUND: Avascular necrosis of the femoral head (ANFH) is the indication for total hip arthroplasty (THA) in patients with Gaucher disease (GD). Due to the rarity of GD, the surgical procedure and long-term outcomes in large patient populations have been insufficiently studied. AIM: This study aimed to analyze the perioperative period as well as medium- and long-term outcomes of THA in patients with GD. METHODS: A retrospective, single-center study was conducted in 26 patients with GD who underwent 30 primary THAs and 9 revision hip arthroplasties between 2005 and 2023. RESULTS: Good and excellent THA outcomes were achieved in 87% of cases, with follow-up periods ranging from 1 to 10 years (median: 7 years). Unsatisfactory results during the 10-year follow-up were due to periprosthetic infection (2 cases) and aseptic loosening (3 cases). Both cases of periprosthetic infection were caused by osteoarticular tuberculosis, which was not detected at the prehospital stage. High intraoperative blood loss was associated with the duration of enzyme replacement therapy (ERT). Blood loss of 1000 mL was reported in 57%, 22%, and 0% of surgeries when ERT lasted less than 5 years, 5–10 years, and more than 10 years, respectively (p = 0.047). Implant survival without revision 3, 6, and 12 years post-surgery was 97%, 93%, and 61%, respectively. At 12 years, the survival rates for cemented and uncemented implants without revision were 33% and 67%, respectively. Twelve years post-surgery, implant survival without revision was 43% for the CoCr/PE bearing surface and 83% for other combinations (ceramic/ceramic, ceramic/PE, and modified metal / PE). CONCLUSION: THA improves quality of life in patients with GD after ANFH. Uncemented implants with ceramic-on-ceramic, ceramic-on-polyethylene, or modified metal-on-polyethylene bearings demonstrated greater longevity and lower revision rates. A high risk of perioperative hemorrhagic complications was observed in patients who received ERT for less than 5 years. The risk of periprosthetic infection was 6.7%, and tuberculosis should be ruled out in such cases.


  • Open Access

    Radiological and morphological characteristics of the femoral head osteonecrosis in type I Gaucher disease

    by Vasily E. Mamonov, Anastasia A. Solovyova, Dmitry I. Chebotarev, Rodion V. Ponomarev, Vladislav A. Nakonechny, Elena A. Lukina, Соловьева Анастасия Александровна

    BACKGROUND: Osteonecrosis of the femoral head in Gaucher disease type I is an irreversible bone manifestation of the disease. The cause and mechanisms of osteonecrosis in Gaucher disease are still unknown, and their clinical and radiological characteristics must be taken into account when choosing treatment strategy. AIM: To analyze the radial and morphological changes in the proximal femur after osteonecrosis of the femoral head in type I Gaucher disease. MATERIALS AND METHODS: The study included 251 adult patients with type I Gaucher disease from the Russian National Registry; histological examination of 22 removed femoral bone fragments obtained during total hip replacement in 20 patients with Gaucher disease and 9 in patients of the control group was performed. RESULTS: Aseptic necrosis of the femoral head was found in 30% adults with Gaucher disease, and in 20% patients it was associated with femoral head collapse. Osteosclerosis of the cancellous bone of the metaphysis, enlargement / swelling of the medullary cavity with secondary osteopenia and osteoporosis of the proximal femoral diaphysis often accompanied osteonecrosis of the femoral head, causing technical difficulties during surgery. The histological findings revealed a picture of chronic bone tissue ischaemia of the proximal femoral metaphysis, which was confirmed by the detection of widespread areas of osteosclerosis on radiography and MRI. Bone marrow infiltration by Gaucher cells in histological preparations persisted regardless of the duration of enzyme replacement therapy against the background of preserved regenerative potential of bone tissue. CONCLUSIONS: The features of the radiological, MRI and histological picture should be taken into account when planning and performing orthopaedic surgery for aseptic necrosis of the femoral head in patients with type I Gaucher disease.


  • Open Access

    Bone Lesions in Adults with Gaucher Disease Type 1: Incidence, Clinical Features, Bone and Joint Complications, as well as Disability Issues

    by Vasilii Evgenevich Mamonov, Yu. A. Chabaeva, R. V. Ponomarev, E. A. Lukina

    BACKGROUND. Although highly effective enzyme replacement therapy (ERT) for Gaucher disease (GD) is accessible and affordable, orthopedic issues in patients appear often to be the main factor leading to their disability. Bone lesions are essentially observed in 100 % of GD patients. The nature and severity of bone and joint changes, however, are reported to be extremely heterogeneous, whereas their incidence and clinical features have until now remained underresearched. AIM. To assess the incidence and clinical value of bone and joint lesions which complicate the course of GD type 1 with bone involvement. MATERIALS & METHODS. This trial enrolled 267 GD type 1 patients aged 17–85 years (median 38 years), who were followed-up at the National Research Center for Hematology from 2004 to 2024. There were 109 men and 158 women. The analysis focused on the following MRI findings: bone marrow infiltration (BMI), Barnett-Nordin cortical index (BNI), bone deformity, osteolytic and osteonecrotic lesions, as well as orthopedic pathologies progressing to disability. RESULTS. BMI was identified in 213/267 (79.8 %) patients. Erlenmeyer flask-like femoral expansion was observed in 95 % patients (n = 254). The mean BNI was 42.9 % (the normal BNI in adult population exceeds 45 %). Low BNI values were associated with osteolytic lesions, disability, and BMI. No significant association of decreased BNI was seen with osteonecroses. The incidence of osteolytic lesions was 11.2 % (n = 30). New osteolytic lesions were reported neither in ERT nor in substrate reduction therapy recipients. Medullary osteonecrosis was detected in 206/267 (77.15 %) patients, and epiphyseal osteonecrosis was identified in 74/267 (27.72 %) patients. Along with osteonecroses, in contrast to osteolytic manifestations, new lesions (n = 8) were reported to occur under long-term (> 5 years) ERT. The rate of bone fractures was 6.7 % (n = 18). In 18 patients, 64 fractures were observed at various locations. Disability associated with bone and joint complications of GD occurred in 58/267 (21.72 %) patients. After reconstructive surgery, including total articular replacement arthroplasties, 37 patients achieved complete functional recovery. CONCLUSION. Bone changes are essentially observed in all adult patients with GD type 1. However, clinical severity and disability of patients depend on secondary bone and joint complications, among them arthroses resulting from epiphyseal osteonecrosis, pathologic fractures, bone and joint infections. These complications developing on effective ERT were identified in 67/267 patients, which accounted for 25 %.

  • Open Access

    Effect of glucocerebrosidase on human bone marrow multipotent mesenchymal stromal

    by V. E. Mamonov, A. V. Sadovskaya, N. A. Petinati, I. N. Shipounova, A. I. Dorofeeva, N. I. Drize, E. A. Lukina

    Introduction. During enzyme replacement therapy in patients with Gaucher disease (GD) with recombinant glucocerebrosidase (GCase), regression of bone manifestations is possible, but with prolonged therapy osteonecrosis may occur. These changes may be due to impaired differentiation of multipotent mesenchymal stromal cells (MSCs).Aim: to study changes in the MSCs of healthy donors and a patient with GD when cultured in the presence of GCase.Material and methods. MSCs were isolated from the bone marrow of 17 healthy donors and a female patient with GD by a standard method and cultured in the presence of various concentrations of GCase after the second passage from 2 to 7 weeks. Cell proliferation and the ability to differentiate were analyzed, including after induction. The assessment was carried out by differential staining, elution, and expression of differentiation marker genes by real-time PCR.Results. Low concentrations of recombinant GCase (0.25–1.5 U/ml) did not affect the proliferative activity of MSCs. Prolonged cultivation of MSCs in the presence of low doses of GCase led to a change in the differentiation potential of these cells in the direction of adipogenesis. Concentrations of GCase of 3–5 U/ml inhibited the proliferation of MSCs and caused significant changes in cell differentiation. High doses of the enzyme (7–10 U/ml) had a cytotoxic effect and led to cell death within one passage. The proliferative and differentiation potential of the MSCs of a patient with GD differed significantly from the cells of healthy donors in all the parameters studied.Conclusion. The cultivation of donor MSCs in the presence of recombinant GCase alters the proliferation and differentiation potential of these cells. These changes depend on the dose of the enzyme in the medium and the duration of cultivation.

  • SURGICAL TREATMENT OF SEVERE KYPHOSCOLIOTIC SPINAL DEFORMITY IN A 12-YEAR-OLD FEMALE PATIENT WITH TYPE 3 GAUCHER DISEASE: A CLINICAL CASE

    by V.S. Pereverzev, Moscow N.N. Priorov National Medical Center Of Traumatology And Orthopedics Of The Ministry Of Healthcare Of Russia, G.B. Movsisyan, S.V. Kolesov, A.I. Kazmin, N.S. Morozova, E.A. Lukina, V.E. Mamonov, R.I. Mustafin, K.V. Savostyanov, et al.

    Gaucher disease (GD) is an autosomal recessive genetic disease characterized by the accumulation of glucocerebroside in the lysosomes of macrophages of the reticuloendothelial system with the development of cytopenia, hepatosplenomegaly, bone lesions, and, in some cases, neurological disorders. Skeletal manifestations vary in severity and usually affect long bones with clinical presentation of bone pain, bone crises, avascular necrosis, decreased bone mineral density, and pathological fractures. Involvement of the spine and chest in the form of their deformities has an unclear mechanism of development and is mostly applied in neuronopathic forms of the disease, in particular, the type 3 GD. The authors represent a unique clinical case of successful treatment of severe kyphoscoliotic deformity in an adolescent with the type 3 GD. The routine monitoring of the spine in patients with chronic neuronopathic GD is necessary in order to perform the timely surgical intervention and to prevent the progression of the spinal deformity and neurological deficit.

  • Open Access

    REVERSIBLE AND IRREVERSIBLE RADIOLOGICAL SIGNS OF BONE INVOLVEMENT IN TYPE I GAUCHER DISEASE

    by А. А. Соловьева, G. A. Yatsyk, R. V. Ponomarev, K. A. Lukina, I. E. Kostina, V. E. Mamonov, E. A. Lukina

    Background. Gaucher disease is an autosomal recessive lysosomal storage disorder caused by deficiency of the enzyme glucocerebrosidase, which is required for the degradation of glycosphingolipids. Skeletal involvement is one of the main manifestations of the disease and is present in 70–100 % of patients. However, the rarity of Gaucher disease and non-specific and heterogeneous nature of its symptoms and radiological signs may impede consideration of this disease in the differential diagnosis.Aim. To describe the radiological signs of bone involvement in type I Gaucher disease and assess the role of MRI in the evaluation of the severity of the disease in newly diagnosed patients.Materials and methods. X-ray and MRI data of 86 treatment-naïve Gaucher patients were included in the retrospective analysis. Bone marrow involvement, as well as bone and joint pathological changes, were evaluated.Results. Radiological signs of bone involvement in Gaucher patients were described and classified into 2 groups, i.e. reversible and irreversible. Such a classification is important in terms of the assessment of the overall disease severity. MRI has proven to be a sensitive method for detection and evaluation of the reversible bone changes in Gaucher patients.Conclusion. Although radiological manifestations of bone involvement in Gaucher patients are typical, they may significantly vary and be present in various combinations. MRI is the gold standard for the assessment of bone marrow changes in patients with Gaucher disease.


  • Prophylaxis with anti‐inhibitor coagulant complex improves health‐related quality of life in haemophilia patients with inhibitors: results from FEIBA NF Prophylaxis Study

    by O. Stasyshyn, S. Antunes, V. Mamonov, X. Ye, J. Epstein, Y. Xiong, S. Tangada

    Summary: The Pro‐FEIBA study reported health‐related quality of life (HRQoL) improved following 6‐month of Factor Eight Inhibitor Bypassing Activity (FEIBA) prophylaxis. This study investigates whether 12‐month of FEIBA prophylaxis improved HRQoL in haemophilia patients with inhibitors. Thirty‐six subjects in a 1‐year prospective, randomized, open‐label, parallel‐design study were randomized to prophylaxis (85 ± 15 U kg−1 every other day) or on‐demand treatment. HRQoL was assessed at screening, 6 and 12‐month termination using the EQ‐5D, Haem‐A‐QoL, Haemo‐QoL and a general pain visual analog scale (VAS). To evaluate changes, paired t‐tests and criteria for minimally important differences were applied. Repeated measures regression tested the association between annualized bleeding rate (ABR) and physical HRQoL. At 6 and 12 months, prophylaxis subjects reported clinically meaningful improvement in EQ‐5D index (mean improvement, 0.10 and 0.08, respectively) and both clinically meaningful and statistically significant improvements in EQ‐VAS scores (16.9 and 15.7, respectively; P < 0.05) vs. baseline. General pain was significantly reduced during prophylaxis at each follow‐up (mean improvement, 20.3 and 23.2, respectively; both P P < 0.05). No statistically significant changes, except for Haem‐A‐QoL Physical Health at 6 months, were observed with on‐demand treatment. ABR was decreased by 72.5% with prophylaxis vs. on‐demand treatment (P = 0.0003) and reduced ABR was associated with better physical HRQoL (P < 0.05). FEIBA prophylaxis significantly reduced ABR and improved HRQoL in inhibitor patients. Subjects with lower ABR reported better physical HRQoL.